हमारा समूह 1000 से अधिक वैज्ञानिक सोसायटी के सहयोग से हर साल संयुक्त राज्य अमेरिका, यूरोप और एशिया में 3000+ वैश्विक सम्मेलन श्रृंखला कार्यक्रम आयोजित करता है और 700+ ओपन एक्सेस जर्नल प्रकाशित करता है जिसमें 50000 से अधिक प्रतिष्ठित व्यक्तित्व, प्रतिष्ठित वैज्ञानिक संपादकीय बोर्ड के सदस्यों के रूप में शामिल होते हैं।
ओपन एक्सेस जर्नल्स को अधिक पाठक और उद्धरण मिल रहे हैं
700 जर्नल और 15,000,000 पाठक प्रत्येक जर्नल को 25,000+ पाठक मिल रहे हैं
Ashraf I Reyad, Ann Dao, Jacfranz J Guiteau, Machaiah M Madhrira, Sridhar R Allam
This case describes successful renal transplantation in an elderly patient following diagnosis with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Forty-six days prior to transplant, a 65-year-old African American Male with end stage renal disease on kidney transplant waitlist, hypertension, hyperlipidemia, and chronic diastolic heart failure presented to the emergency department and was diagnosed with SARS-CoV-2 pneumonia. Following treatment with dexamethasone and convalescent plasma therapy during the two-week inpatient admission, the patient was discharged home. Subsequently, the patient was reactivated on waitlist following two confirmatory negative SARS-CoV-2 PCR tests. Upon the transplant admission, repeat PCR and rapid antigen tests resulted negative. The patient received anti-thymocyte globulin 4.5 mg/kg as induction therapy. Post-operative course was uneventful with immediate graft function. Maintenance therapy included tacrolimus, mycophenolate, and corticosteroid taper. A SARS-CoV-2 IgG antibody test collected during the admission resulted positive. The patient was discharged on post-operative day 4 with a serum creatinine of 1.6 mg/dL. At 2 month following transplant, the patient remains asymptomatic with stable renal function. In this case report, the patient safely received T-cell depleting induction therapy following SAR-CoV-2 pneumonia. Positive SARS-CoV-2 antibodies at the time of transplant may have provided protection against recurrent infection.